NO20022925D0 - EP4 reseptor selektive agonister for behandling av osteoporose - Google Patents

EP4 reseptor selektive agonister for behandling av osteoporose

Info

Publication number: NO20022925D0
Authority: NO; Norway
Prior art keywords: osteoporosis; treatment; selective agonists; receptor selective; receptor
Prior art date: 1999-12-22

Application number

NO20022925A

Other languages

English (en)

Other versions

NO20022925L (no

Inventor

Kimberly O'keefe Cameron

Huazhu Ke

Bruce Allen Lefker

David Duane Thompson

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-22

Filing date

2002-06-18

Publication date

2002-06-18

2002-06-18 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2002-06-18 Publication of NO20022925D0 publication Critical patent/NO20022925D0/no

2002-06-18 Publication of NO20022925L publication Critical patent/NO20022925L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

NO20022925A 1999-12-22 2002-06-18 EP4 reseptor selektive agonister for behandling av osteoporose NO20022925L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US17135399P	1999-12-22	1999-12-22
PCT/IB2000/001711 WO2001046140A1 (en)	1999-12-22	2000-11-20	Ep4 receptor selective agonists in the treatment of osteoporosis

Publications (2)

Publication Number	Publication Date
NO20022925D0 true NO20022925D0 (no)	2002-06-18
NO20022925L NO20022925L (no)	2002-06-18

Family

ID=22623430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022925A NO20022925L (no)	1999-12-22	2002-06-18	EP4 reseptor selektive agonister for behandling av osteoporose

Country Status (36)

Country	Link
US (2)	US6737437B2 (no)
EP (1)	EP1110949B1 (no)
JP (1)	JP2001181210A (no)
KR (1)	KR100419681B1 (no)
CN (1)	CN1413190A (no)
AP (2)	AP2002002555A0 (no)
AT (1)	ATE250575T1 (no)
AU (2)	AU1293101A (no)
BG (1)	BG106882A (no)
BR (1)	BR0016560A (no)
CA (1)	CA2329678A1 (no)
CO (1)	CO5251453A1 (no)
CR (1)	CR6678A (no)
CZ (1)	CZ20022048A3 (no)
DE (1)	DE60005471T2 (no)
DK (1)	DK1110949T3 (no)
EA (1)	EA005293B1 (no)
EE (1)	EE200200355A (no)
ES (1)	ES2204458T3 (no)
GE (1)	GEP20043203B (no)
HR (1)	HRP20020537A2 (no)
HU (1)	HUP0005001A3 (no)
IL (1)	IL140325A0 (no)
IS (1)	IS6388A (no)
MA (1)	MA26852A1 (no)
MX (1)	MXPA02006322A (no)
NO (1)	NO20022925L (no)
OA (1)	OA12117A (no)
PE (1)	PE20010953A1 (no)
PL (1)	PL356662A1 (no)
PT (1)	PT1110949E (no)
SK (1)	SK8552002A3 (no)
TR (2)	TR200201643T2 (no)
UA (1)	UA72293C2 (no)
WO (1)	WO2001046140A1 (no)
ZA (1)	ZA200007694B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010056060A1 (en) *	2000-02-07	2001-12-27	Cameron Kimberly O.	Treatment of osteoporsis with EP2/EP4 receptor selective agonists
DK1339678T3 (da) *	2000-11-27	2008-02-04	Pfizer Prod Inc	Selektive agonister til EP4-receptor til behandling af osteoporose
CN100371322C (zh) *	2001-07-16	2008-02-27	霍夫曼-拉罗奇有限公司	作为前列腺素类化合物激动剂的2-吡咯烷酮衍生物
ATE315022T1 (de) *	2001-07-16	2006-02-15	Hoffmann La Roche	Prostaglandinanaloga als ep4-rezeptoragonisten
BR0211364A (pt)	2001-07-23	2004-07-13	Ono Pharmaceutical Co	Composição farmacêutica para tratamento de doenças associadas com redução na massa óssea compreendendo o agonista ep4 como componente ativo
ES2360604T3 (es) *	2001-07-23	2011-06-07	Ono Pharmaceutical Co., Ltd.	Remedios para enfermedades con pérdida de masa osea que tienen como ingrediente activo agonistas de ep4.
US20040258730A1 (en) *	2001-11-12	2004-12-23	Yasuhiko Tabata	Persistent filmy preparation for topical administration containing prostglandin derivative
JP2005519879A (ja) *	2001-12-03	2005-07-07	メルク　エンド　カムパニー　インコーポレーテッド	Ｅｐ４受容体作動剤とその組成物および方法
US20040254230A1 (en) *	2001-12-03	2004-12-16	Ogidigben Miller J.	Method for treating ocular hypertension
ES2337887T3 (es)	2001-12-20	2010-04-30	Merck Serono Sa	Derivados de pirrolidina en calidad de moduladores de prostaglandina.
JP4547912B2 (ja)	2002-03-05	2010-09-22	小野薬品工業株式会社	８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
JP2005526080A (ja) *	2002-03-18	2005-09-02	ファイザー・プロダクツ・インク	肝不全、動脈管閉鎖、緑内障又は高眼圧の治療のための選択的ｅｐ４受容体アゴニストの使用
AU2011202937B2 (en) *	2002-05-14	2012-06-07	Allergan, Inc.	8-azaprostaglandin analogs as agents for lowering intraocular pressure
US6573294B1 (en) *	2002-05-14	2003-06-03	Allergan, Inc.	8-azaprostaglandin analogs as agents for lowering intraocular pressure
CA2488001C (en)	2002-06-06	2011-03-22	Merck Frosst Canada & Co.	1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
US7419999B2 (en)	2002-06-10	2008-09-02	Applied Research Systems Ars Holding N.V.	Gamma lactams as prostaglandin agonists and use thereof
US7547715B2 (en)	2002-10-10	2009-06-16	Ono Pharmaceutical Co., Ltd.	Endogenous repair factor production accelerator
US7196082B2 (en)	2002-11-08	2007-03-27	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
EP1581503A4 (en)	2002-11-08	2007-07-25	Merck & Co Inc	OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
US7053085B2 (en)	2003-03-26	2006-05-30	Merck & Co. Inc.	EP4 receptor agonist, compositions and methods thereof
MXPA05007341A (es) *	2003-01-10	2005-09-30	Hoffmann La Roche	Derivados de 2-piperidona como agonistas de prostaglandina.
US7256211B1 (en)	2003-01-21	2007-08-14	Ono Pharmaceutical Co., Ltd.	8-azaprostaglandin derivatives and medical use thereof
WO2004078103A2 (en)	2003-03-03	2004-09-16	Applied Research Systems Ars Holding N.V.	G-lactam derivatives as prostaglandin agonists
US6734201B1 (en)	2003-06-02	2004-05-11	Allergan, Inc.	8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en) *	2003-06-02	2004-05-11	Allergan, Inc.	3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7179820B2 (en)	2003-06-06	2007-02-20	Allergan, Inc.	Piperidinyl prostaglandin E analogs
JP2006528154A (ja)	2003-07-18	2006-12-14	アプライドリサーチシステムズエーアールエスホールディングナームロゼフェンノートシャップ	プロスタグランジン受容体のモジュレータとしてのヒドラジド誘導体
JP2007504228A (ja)	2003-09-02	2007-03-01	メルク　エンド　カムパニー　インコーポレーテッド	高眼圧症を治療するための眼組成物
KR20060090801A (ko)	2003-09-04	2006-08-16	머크 앤드 캄파니 인코포레이티드	고안압증 치료용 안용 조성물
US7494983B2 (en)	2003-09-04	2009-02-24	Merck & Co. Inc.	Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
EP1723132A1 (en)	2004-02-12	2006-11-22	Asterand Uk Limited	Ep2 receptor agonists
AU2005274972A1 (en)	2004-07-20	2006-02-23	Merck & Co., Inc.	Ophthalmic compositions for treating ocular hypertension
EP1824819B1 (en)	2004-12-06	2010-01-20	Merck Serono SA	Pyrrolidin-2-one derivatives for use as dp1 receptor agonists
US7531533B2 (en)	2005-01-27	2009-05-12	Asahi Kasei Pharma Corporation	6-Membered heterocyclic compound and use thereof
WO2006118173A1 (ja)	2005-04-28	2006-11-09	Ono Pharmaceutical Co., Ltd.	経皮吸収製剤
KR100686186B1 (ko) *	2005-06-13	2007-02-26	영진종합건설 주식회사	교량용 배수 구조물
WO2007017687A2 (en)	2005-08-09	2007-02-15	Asterand Uk Limited	Ep2 receptor agonists
EP2085088A4 (en)	2006-10-26	2012-08-29	Ono Pharmaceutical Co	ADHESIVE PREPARATION
EP2094839B1 (en)	2006-12-08	2020-02-05	University of Rochester	Expansion of hematopoietic stem cells
WO2009065081A2 (en)	2007-11-14	2009-05-22	Cayman Chemical Company	Prostaglandin e1 and e2 analogs for the treatment of various medical conditions
CA2738045C (en)	2010-05-28	2019-02-19	Simon Fraser University	Conjugate compounds, methods of making same, and uses thereof
MX2014000971A (es)	2011-08-02	2014-02-27	Ono Pharmaceutical Co	Agente mejorador de la funcion diastolica ventricular izquierda.
PL2875022T3 (pl)	2012-07-19	2017-06-30	Cayman Chemical Company, Incorporated	Związki difluorolaktamowe jako agoniści selektywni względem receptora EP4 do zastosowania w leczeniu chorób i stanów, w których pośredniczy EP4
JP6400479B2 (ja)	2012-10-29	2018-10-03	株式会社カルディオ	肺疾患特異的治療剤
US9676712B2 (en)	2013-03-15	2017-06-13	Cayman Chemical Company, Inc.	Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9688627B2 (en) *	2013-03-15	2017-06-27	Cayman Chemical Company, Inc.	Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
KR20160048054A (ko)	2013-07-19	2016-05-03	카이맨 케미칼 컴파니 인코포레이티드	골 성장의 촉진을 위한 방법, 시스템 및 조성물
CN114404588A (zh)	2013-08-09	2022-04-29	阿德利克斯公司	用于抑制磷酸盐转运的化合物和方法
WO2015056504A1 (ja)	2013-10-15	2015-04-23	小野薬品工業株式会社	薬剤溶出性ステントグラフト
WO2016199111A1 (en)	2015-06-12	2016-12-15	Simon Fraser University	Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
WO2020237096A1 (en)	2019-05-21	2020-11-26	Ardelyx, Inc.	Combination for lowering serum phosphate in a patient

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR897566A (fr)	1942-08-28	1945-03-26	Bopp & Reuther Gmbh	Machine à rotors
US3528961A (en)	1966-08-16	1970-09-15	Allied Chem	Monoazo dyes from e-caprolactam
US3780095A (en)	1970-04-08	1973-12-18	Byk Gulden Lomberg Chem Fab	Acylated anilino-carboxylic acids and their salts
US3987091A (en)	1973-04-12	1976-10-19	Merck & Co., Inc.	11,12-secoprostaglandins
US4033996A (en)	1973-04-25	1977-07-05	Merck & Co., Inc.	8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
SE7414770L (no)	1973-12-13	1975-06-16	Merck & Co Inc
DK366475A (da)	1974-08-30	1976-03-01	Merck & Co Inc	Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US3991106A (en)	1974-09-13	1976-11-09	Merck & Co., Inc.	16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4055596A (en)	1974-09-13	1977-10-25	Merck & Co., Inc.	11,12-Seco-prostaglandins
US4113873A (en)	1975-04-26	1978-09-12	Tanabe Seiyaku Co. Ltd.	8-azaprostanoic acid derivatives
DE2528664A1 (de) *	1975-06-27	1977-01-13	Hoechst Ag	Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en)	1976-03-31	1979-11-30	Labaz	8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de)	1976-05-04	1977-11-17	Hoechst Ag	Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en)	1976-08-06	1979-12-04	Pfizer Inc.	1,5-Disubstituted-2-pyrrolidones
US4175203A (en)	1976-12-17	1979-11-20	Merck & Co., Inc.	Interphenylene 11,12-secoprostaglandins
US4243678A (en)	1977-12-30	1981-01-06	Byk Gulden Lomberg Chemische Fabrik Gmbh	Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de)	1980-01-07	1981-07-09	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de)	1980-11-11	1982-06-24	A. Nattermann & Cie GmbH, 5000 Köln	N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA1214170A (fr)	1981-06-16	1986-11-18	Patrick Choay	Procedes de preparation de nouveaux composes du type arylbenzenesulfonamide
AU6427596A (en) *	1992-04-14	1996-10-31	Alfred Maximillian Stessl	A boat hull
TW383306B (en)	1992-12-22	2000-03-01	Lilly Co Eli	New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
CA2275595C (en) *	1996-12-20	2003-08-05	Pfizer Inc.	Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
GB2330307A (en) *	1998-02-07	1999-04-21	Glaxo Group Ltd	EP4 Receptor antagonists as bone resorption inhibitors
WO2000021542A1 (en) *	1998-10-15	2000-04-20	Merck & Co., Inc.	Methods for stimulating bone formation
EP1148877A4 (en) *	1998-10-15	2003-01-22	Merck & Co Inc	METHOD FOR INHIBITING BONE RESORPTION

2000
- 2000-11-20 AP APAP/P/2002/002555A patent/AP2002002555A0/en unknown
- 2000-11-20 CN CN00817566A patent/CN1413190A/zh active Pending
- 2000-11-20 AU AU12931/01A patent/AU1293101A/en not_active Abandoned
- 2000-11-20 EE EEP200200355A patent/EE200200355A/xx unknown
- 2000-11-20 EA EA200200505A patent/EA005293B1/ru not_active IP Right Cessation
- 2000-11-20 UA UA2002065186A patent/UA72293C2/uk unknown
- 2000-11-20 AP APAP/P/2001/002357A patent/AP2001002357A0/en unknown
- 2000-11-20 CZ CZ20022048A patent/CZ20022048A3/cs unknown
- 2000-11-20 BR BR0016560-3A patent/BR0016560A/pt not_active IP Right Cessation
- 2000-11-20 WO PCT/IB2000/001711 patent/WO2001046140A1/en not_active Ceased
- 2000-11-20 TR TR2002/01643T patent/TR200201643T2/xx unknown
- 2000-11-20 PL PL00356662A patent/PL356662A1/xx not_active Application Discontinuation
- 2000-11-20 OA OA1200200177A patent/OA12117A/en unknown
- 2000-11-20 SK SK855-2002A patent/SK8552002A3/sk unknown
- 2000-11-20 GE GEAP20006502A patent/GEP20043203B/en unknown
- 2000-11-20 HR HRP20020537 patent/HRP20020537A2/hr not_active Application Discontinuation
- 2000-11-20 MX MXPA02006322A patent/MXPA02006322A/es active IP Right Grant
- 2000-12-11 PT PT00311034T patent/PT1110949E/pt unknown
- 2000-12-11 DK DK00311034T patent/DK1110949T3/da active
- 2000-12-11 DE DE60005471T patent/DE60005471T2/de not_active Expired - Fee Related
- 2000-12-11 EP EP00311034A patent/EP1110949B1/en not_active Expired - Lifetime
- 2000-12-11 ES ES00311034T patent/ES2204458T3/es not_active Expired - Lifetime
- 2000-12-11 TR TR2003/01841T patent/TR200301841T4/xx unknown
- 2000-12-11 AT AT00311034T patent/ATE250575T1/de not_active IP Right Cessation
- 2000-12-14 IL IL14032500A patent/IL140325A0/xx unknown
- 2000-12-15 US US09/738,670 patent/US6737437B2/en not_active Expired - Fee Related
- 2000-12-19 KR KR10-2000-0078214A patent/KR100419681B1/ko not_active Expired - Fee Related
- 2000-12-19 PE PE2000001368A patent/PE20010953A1/es not_active Application Discontinuation
- 2000-12-20 CA CA002329678A patent/CA2329678A1/en not_active Abandoned
- 2000-12-20 ZA ZA200007694A patent/ZA200007694B/xx unknown
- 2000-12-20 AU AU72393/00A patent/AU763983B2/en not_active Ceased
- 2000-12-21 HU HU0005001A patent/HUP0005001A3/hu unknown
- 2000-12-22 JP JP2000390594A patent/JP2001181210A/ja not_active Ceased
- 2000-12-22 CO CO00097391A patent/CO5251453A1/es not_active Application Discontinuation
2001
- 2001-11-16 US US09/991,585 patent/US6642266B2/en not_active Expired - Fee Related
2002
- 2002-05-17 IS IS6388A patent/IS6388A/is unknown
- 2002-06-12 CR CR6678A patent/CR6678A/es not_active Application Discontinuation
- 2002-06-13 MA MA26686A patent/MA26852A1/fr unknown
- 2002-06-18 NO NO20022925A patent/NO20022925L/no not_active Application Discontinuation
- 2002-06-28 BG BG106882A patent/BG106882A/xx unknown

Also Published As

Publication number	Publication date
UA72293C2 (en)	2005-02-15
DE60005471T2 (de)	2004-04-22
IL140325A0 (en)	2002-02-10
AP2001002357A0 (en)	2001-12-31
GEP20043203B (en)	2004-03-25
IS6388A (is)	2002-05-17
HRP20020537A2 (en)	2004-12-31
OA12117A (en)	2006-05-04
HUP0005001A3 (en)	2002-01-28
BG106882A (en)	2003-02-28
ZA200007694B (en)	2002-06-20
CA2329678A1 (en)	2001-06-22
CN1413190A (zh)	2003-04-23
CO5251453A1 (es)	2003-02-28
EA200200505A1 (ru)	2002-12-26
BR0016560A (pt)	2002-09-10
DK1110949T3 (da)	2003-11-24
HUP0005001A2 (hu)	2001-12-28
ATE250575T1 (de)	2003-10-15
CR6678A (es)	2004-01-14
EA005293B1 (ru)	2004-12-30
AP2002002555A0 (en)	2002-06-30
US20020040149A1 (en)	2002-04-04
ES2204458T3 (es)	2004-05-01
CZ20022048A3 (cs)	2004-03-17
TR200301841T4 (tr)	2004-01-21
KR20010067415A (ko)	2001-07-12
JP2001181210A (ja)	2001-07-03
MXPA02006322A (es)	2002-12-13
US6642266B2 (en)	2003-11-04
US20010047105A1 (en)	2001-11-29
AU7239300A (en)	2001-06-28
EP1110949A1 (en)	2001-06-27
SK8552002A3 (en)	2003-09-11
DE60005471D1 (de)	2003-10-30
PL356662A1 (en)	2004-06-28
TR200201643T2 (tr)	2002-11-21
WO2001046140A1 (en)	2001-06-28
HU0005001D0 (no)	2001-02-28
MA26852A1 (fr)	2004-12-20
NO20022925L (no)	2002-06-18
AU1293101A (en)	2001-07-03
PE20010953A1 (es)	2001-09-25
EP1110949B1 (en)	2003-09-24
US6737437B2 (en)	2004-05-18
PT1110949E (pt)	2003-12-31
KR100419681B1 (ko)	2004-02-21
EE200200355A (et)	2003-10-15
AU763983B2 (en)	2003-08-07

Publication	Publication Date	Title
NO20022925D0 (no)	2002-06-18	EP4 reseptor selektive agonister for behandling av osteoporose
NO20032360D0 (no)	2003-05-26	EP4 reseptor selektive agonister for behandling av osteoporose
NO20016246L (no)	2002-03-04	Selektiv iGluR5 reseptorantagonist for behandling av migrene
PT1189916E (pt)	2004-03-31	N-pirazole agonistas do receptor a2a
NO20014379D0 (no)	2001-09-10	Anvendelse av Xenon for behandling av Neurointoksikasjoner
NO20013380L (no)	2001-09-07	2-aminobenzoksazinonderivater for behandling av fedme
NO20022105L (no)	2002-07-02	Positive modulatorer av nikotiniske reseptoragonister
NO20013381D0 (no)	2001-07-06	2-oksybenzoksazinonderivater for behandling av fedme
NO20034122L (no)	2003-09-16	Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
NO20013369D0 (no)	2001-07-06	Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
NO20020574D0 (no)	2002-02-05	Substituerte 1,5-dihydropyrrol-2-onderivater som er virksomme som NMDA-reseptorantagonister for behandlingen av smertetilstanden
DE60028368D1 (de)	2006-07-06	Agonisten des peroxisom aktivator-responsiven rezeptors
NO20022009L (no)	2002-07-02	Positive modulatorer av nikotiniske reseptoragonister
NO20013997D0 (no)	2001-08-16	Reseptoranalyse
AU7788500A (en)	2001-05-08	Use of substance p antagonists for influencing the circadian timing system
NO20021295L (no)	2002-05-14	Nikotinsyreacetylcholin-reseptor
NO20022142D0 (no)	2002-05-03	Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
FI5227U1 (fi)	2002-01-29	Laitteisto laastin jakelemiseksi
DK1200402T3 (da)	2005-10-03	Substituerede 1,5-dihydropyrrol-2-on-derivater med virkning som NMDA-receptorantagonister til behandling af smertetilstande
TW376691U (en)	1999-12-11	Structure of combination device for the flashing ornaments

Legal Events

Date	Code	Title	Description
2006-07-03	FC2A	Withdrawal, rejection or dismissal of laid open patent application